2. Academic Validation
  3. A novel small molecule aurora kinase inhibitor attenuates breast tumor-initiating cells and overcomes drug resistance

A novel small molecule aurora kinase inhibitor attenuates breast tumor-initiating cells and overcomes drug resistance

  • Mol Cancer Ther. 2014 Aug;13(8):1991-2003. doi: 10.1158/1535-7163.MCT-13-1029.
Fei-Meng Zheng 1,  Zi-Jie Long 2,  Zhi-Jie Hou 3,  Yu Luo 4,  Ling-Zhi Xu 3,  Jiang-Long Xia 3,  Xiao-Ju Lai 5,  Ji-Wei Liu 3,  Xi Wang 5,  Muhammad Kamran 3,  Min Yan 5,  Shu-Juan Shao 6,  Eric W-F Lam 7,  Shao-Wu Wang 3,  Gui Lu 8,  Quentin Liu 9
Affiliations

Affiliations

  • 1 Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center of Cancer Medicine; Institute of Cancer Stem Cell, Dalian Medical University; Institute of Cancer Stem Cell, Institute of Cancer Stem Cell - First Affiliated Hospital Collaborative Innovation Center of Oncology;
  • 2 Department of Hematology, Third Affiliated Hospital, Sun Yat-sen University;
  • 3 Institute of Cancer Stem Cell, Institute of Cancer Stem Cell - First Affiliated Hospital Collaborative Innovation Center of Oncology;
  • 4 Institute of Medicinal Chemistry, School of Pharmaceutical Sciences, Sun Yat-sen University, Guangzhou;
  • 5 Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center of Cancer Medicine; Institute of Cancer Stem Cell, Dalian Medical University;
  • 6 Department of Histology and Embryology, Dalian Medical University, Dalian, China; and.
  • 7 Department of Surgery and Cancer, Imperial Centre for Translational and Experimental Medicine (ICTEM), Imperial College London, London, United Kingdom.
  • 8 Institute of Medicinal Chemistry, School of Pharmaceutical Sciences, Sun Yat-sen University, Guangzhou; [email protected] [email protected] [email protected].
  • 9 Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center of Cancer Medicine; Institute of Cancer Stem Cell, Dalian Medical University; Department of Hematology, Third Affiliated Hospital, Sun Yat-sen University; Institute of Cancer Stem Cell, Institute of Cancer Stem Cell - First Affiliated Hospital Collaborative Innovation Center of Oncology; [email protected] [email protected] [email protected].
PMID: 24899685 DOI: 10.1158/1535-7163.MCT-13-1029
Abstract

Chemoresistance is a major cause of Cancer treatment failure. Tumor-initiating cells (TIC) have attracted a considerable amount of attention due to their role in chemoresistance and tumor recurrence. Here, we evaluated the small molecule Aurora Kinase Inhibitor AKI603 as a novel agent against TICs in breast Cancer. AKI603 significantly inhibited Aurora-A (AurA) kinase and induced cell-cycle arrest. In addition, the intragastric administration of AKI603 reduced xenograft tumor growth. Interestingly, we found that breast Cancer cells that were resistant to epirubicin expressed a high level of activated AurA and also have a high CD24(Low)/CD44(High) TIC population. The inhibition of AurA kinase by AKI603 abolished the epirubicin-induced enrichment of TICs. Moreover, AKI603 suppressed the capacity of cells to form mammosphere and also suppressed the expression of self-renewal genes (β-catenin, c-Myc, Sox2, and Oct4). Thus, our work suggests the potential clinical use of the small molecule Aurora Kinase Inhibitor AKI603 to overcome drug resistance induced by conventional chemotherapeutics in breast Cancer.

Figures
Products